| Literature DB >> 26666459 |
Leslie Martin1, Miriam Tova Harris2, Annie Brooks1,3, Cheryl Main3,4, Dominik Mertz5,6,7,8,9.
Abstract
BACKGROUND: Infectious disease (ID) consultations have been shown to increase adherence to guidelines and decrease mortality for patients with Staphylococcus aureus bacteremia (SAB). Here, we assessed the impact of a mandatory ID consultation policy for SAB.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26666459 PMCID: PMC4678701 DOI: 10.1186/s12879-015-1296-y
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Fig. 1Study inclusion and outcomes. Abbreviations: s. aureus: Staphylococcus aureus; AMA: against medical advice
Patient characteristics of the baseline and intervention patient population
| 2011 (Baseline) | 2012 (Intervention) | Odds ratio (95 % CI) | P value | |
|---|---|---|---|---|
| Total | 128 | 124 | ||
| Age | 63.4 | 62.8 | 0.29 | |
| Male | 74 (57.8 %) | 74 (59.7 %) | 1.1 (0.7–1.7) | 0.76 |
| Hospital 1 (vs. Hospital 2) | 69 (53.9 %) | 64 (51.6 %) | 0.9 (0.6–1.5) | 0.71 |
| MSSA (vs. MRSA) | 97 (75.8 %) | 100 (80.6 %) | 1.3 (0.7–2.4) | 0.35 |
| Palliative | 5 (3.9 %) | 8 (6.5 %) | 1.7 (0.5–5.3) | 0.36 |
| ID Involvement | ||||
| Overall | 93/128 (72.7 %) | 103/124 (83.1 %) | 1.9 (1.1–3.3) | 0.047 |
| Hospital 1 | 61/69 (88.4 %) | 56/64 (87.5 %) | 0.9 (0.3–2.5) | 0.87 |
| Hospital 2 | 32/59 (54.2 %) | 47/60 (78.3 %) | 3.0 (1.4–10.0) | 0.005 |
| Time to ID Involvement | ||||
| Days, median (IQR) | 2 (1–3) | 1 (1–2) | n/a | 0.001 |
| Mortality | ||||
| Overall | 37/128 (28.9 %) | 35/124 (28.2 %) | 0.97 (0.6–1.7) | 0.91 |
| Palliative cases excluded | 34/123 (27.6 %) | 31/116 (26.7 %) | 0.96 (0.5–1.7) | 0.87 |
| Relapse | 0 | 0 | n/a | n/a |
| Readmission | 1/128 (0.01 %) | 1/124 (0.01 %) | 1.0 (0.6–16.7) | 0.98 |
Abbreviations: MSSA methicillin susceptible Staphylococcus aureus, MRSA methicillin Resistant Staphylococcus aureus, CI confidence interval, ID Infectious Disease, IQR interquartile range, n/a not applicable
Outcomes of the control and intervention patient population in non-palliative patients who survived the minimum treatment period (at least 13 days)
| Adherence to IDSA Guidelines | ||||
|---|---|---|---|---|
| 2011 (Baseline) | 2012 (Intervention) | Odds ratio (95 % CI) | P value | |
| Overall | 65/102 (63.7 %) | 77/96 (80.2 %) | 2.3 (1.2–4.4) | 0.01 |
| Hospital 1 | 38/55 (69.1 %) | 41/50 (82 %) | 2.1 (0.8–5.1) | 0.12 |
| Hospital 2 | 27/47 (57.4 %) | 36/46 (78.3 %) | 2.7 (1.1–6.6) | 0.03 |
| Reason for non-adherence to guidelines | ||||
| No TTE | 15/102 (14.7 %) | 7/96 (7.3 %) | 0.46 (0.18–1.17) | 0.10 |
| No Follow-up cultures | 13/102 (12.7 %) | 10/96 (10.4 %) | 0.80 (0.33–1.91) | 0.61 |
| Inappropriate Antibiotic Duration | 12/102 (11.8 %) | 3/96 (3.1 %) | 0.24 (0.07–0.88) | 0.02 |
| No source control (cases with source) | 1/66 (1.5 %) | 0/61 (0.0 %) | 0.99 (0.96–1.01) | 0.34 |
| Greater than one of the above reasons for non–adherence to guidelines | 12/102 (11.8 %) | 3/96 (3.1 %) | 0.24 (0.07–0.89) | 0.02 |
Abbreviations: IDSA infectious disease society of America, CI confidence interval, TTE trans-thoracic echocardiogram
Empiric therapy used in treatment of suspected SAB
| Empiric therapy | 2011 (Baseline) | 2012 (Intervention) | Odds ratio (95 % CI) | P value |
|---|---|---|---|---|
| Solely Cefazolin or Cloxacillin | 14/102 (13.7 %) | 3/96 (3.1 %) | 0.20 (0.06–0.73) | 0.01 |
| Solely Vancomycin | 32/102 (31.4 %) | 36/96 (37.5 %) | 1.31 (0.73–2.36) | 0.36 |
| Vancomycin + Cefazolin/Cloxacillin | 14/102 (13.7 %) | 22/96 (22.9 %) | 1.87 (0.89–3.91) | 0.09 |
| Vancomycin + other beta-lactam | 30/102 (29.4 %) | 24/96 (25 %) | 0.80 (0.43–1.50) | 0.49 |
| No therapy | 2/102 (2.0 %) | 0/96 | 0.98 (0.96–1.01) | 0.17 |
| Other empiric therapy | 10/102 (9.8 %) | 11/96 (11.5 %) | 1.19 (0.48–2.45) | 0.71 |
Abbreviation: CI confidence interval